NEW YORK / Nov 08, 2023 / Business Wire / DocGo, a leading provider of technology-enabled mobile health services (Nasdaq: DCGO), today announced that the company will be participating in the following investor conferences during the month of November.
Needham & Company 4th Annual Tech Week
November 15, 2023 – Virtual 1x1 investor meetings, contact your Needham representative for additional information.
Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
November 16, 2023 – 1x1 investor meetings, contact your Canaccord representative for additional information.
BTIG Digital Health Forum
November 20, 2023 – Virtual 1x1 investor meetings, contact your BTIG representative for additional information.
About DocGo
DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring, and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
| Last Trade: | US$4.25 |
| Daily Change: | 0.03 0.71 |
| Daily Volume: | 258,251 |
| Market Cap: | US$431.500M |
December 18, 2024 December 10, 2024 December 04, 2024 November 26, 2024 November 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
